A multicenter pooled review offers insights into the clinical treatment of nccRCC and sarcomatoid/rhabdoid RCC patients, demonstrating the differential activity of PD-1/PD-L1 blockers in patients with different RCC histologies (171). This evidence concerns the gene CD274 and renal cell adenocarcinoma.